To the full analysis
Alpha Teknova stock: growth
TKNOAlpha Teknova reported $40.52M in revenue for fiscal 2025, up 7.4% on the prior year, up 5.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.4%
per year from 2019 to 2025, per share −28.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 5.3% | 12.4% |
| Revenue per share | −37.4% | −28.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $20.09M | −$1.31M | −$477K |
| 2020 | $31.3M | $3.57M | −$2.96M |
| 2021 | $36.89M | −$9.8M | −$28.95M |
| 2022 | $41.42M | −$47.47M | −$55.55M |
| 2023 | $36.68M | −$36.78M | −$26.75M |
| 2024 | $37.75M | −$26.75M | −$13.52M |
| 2025 | $40.52M | −$17.26M | −$9.79M |
Revenue by segment
How Alpha Teknova, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Lab Essentials77%
- Clinical Solutions19%
- Other5%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Lab Essentials | $27.18M | $31.77M | $28.8M | $28.88M | $31.04M | 76.6% |
| Clinical Solutions | $6.79M | $8.45M | $6.74M | $7.1M | $7.65M | 18.9% |
| Other | $2.92M | $1.2M | $1.15M | $1.77M | $1.83M | 4.5% |
| Total revenue | $36.89M | $41.42M | $36.68M | $37.75M | $40.52M | 100% |
Revenue by region
Where Alpha Teknova, Inc. generates its revenue.
- United States94%
- Outside the US6%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $35.81M | $40.1M | $35M | $35.92M | $38.25M | 94.4% |
| Outside the US | $1.09M | $1.32M | $1.68M | $1.83M | $2.27M | 5.6% |
| Total revenue | $36.89M | $41.42M | $36.68M | $37.75M | $40.52M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.